Do Stock Screeners Work? What a Screen Can and Cannot Tell You

Stock screeners work, but only at the job they are actually built for: turning thousands of tickers into a short list you can read in an afternoon. They do that extremely well, and for that they are worth the money. What a screener cannot do is tell you whether the rule behind your filter has ever made money. A screen is a query, not evidence, and the entire distance between those two words is where portfolios get hurt.

Put plainly: the screen finds candidates, the backtest finds out if the idea was ever any good. Almost everyone buys the first tool and skips the second, then blames the first when the shortlist disappoints.

What do stock screeners actually do?

A screener runs a filter over a database of current fundamentals and price data and returns the rows that match. Ask for US-listed stocks with a market cap above $2 billion, a P/E under 15, revenue growth above 10%, and price above the 200-day moving average, and it hands you the 40 names that satisfy all four conditions right now.

The important word is "now". A standard screen has no memory. It knows what is true today; it knows nothing about what happened the last time these conditions were true, or whether stocks matching them went on to beat the market or trail it badly for a decade. The output looks like a conclusion and is actually a starting point.

What a screen proves, and what it never proves

Four of those six are the questions that decide whether you make money. A screener answers none of them, and it never claimed to. The failure is in how we use the tool, not in the tool.

The three ways screens quietly mislead

Survivorship bias. Screens run on the companies that exist today. Every company that went to zero, got delisted, or was acquired at a discount is invisible. A value screen that looks great against today's universe is grading a class from which the failures have already been expelled.

The value trap. A low P/E is not a discovery; it is a fact the whole market can see. It usually means the market expects earnings to fall. Screening on cheapness alone reliably produces a list of companies that are cheap for excellent reasons, and only a test across full cycles tells you whether the cheap ones as a group recovered.

Filter tinkering. Add enough conditions and any screen produces a list you like. Six filters tuned until the output "looks right" is not analysis; it is fitting a query to your prior belief. The tell is that you stopped adjusting when you agreed with the result.

Are stock screeners worth it?

Yes, and they are cheap relative to what they replace. Finviz Elite lists at $39.50 per month or $299.50 per year and its free tier is enough for a lot of people. Koyfin puts screening in its Plus plan at $39 per month, alongside 10-year financials. Both prices were checked in July 2026. Set against the hours of manual filtering they eliminate, a screener is one of the easier subscriptions in this category to justify.

The mistake is thinking that spend completes the workflow. It buys you step one of two. The second step, testing whether the rule that generated the shortlist has ever worked, is a different tool, and skipping it is how a $40 screener ends up costing thousands.

How to use a stock screener properly

1. Write the thesis before the filter. Say out loud what you believe, for example: "profitable mid-caps trading below their 5-year average multiple recover within two years." A screen built from a stated belief is testable. A screen built by twisting sliders is not.
2. Keep the screen coarse. Three or four conditions, not nine. Every extra filter narrows the sample and raises the chance you have fitted the query to noise.
3. Test the rule, not just the names. Take the logic behind the screen and run it against history: what did this rule do across 20+ years of adjusted daily prices, with costs charged, against simply holding an index fund?
4. Read the drawdown before the return. A rule that returned 14% a year and fell 55% in the middle is a rule almost nobody actually holds. Survivability beats optimality.
5. Then read the companies. Only after the rule survives does a name-by-name fundamentals read become worth your evening.

Steps 1, 2, and 5 are the screener's job. Steps 3 and 4 are the bench's, and they are the ones that separate an idea that works from an idea that merely sounds right.

Past performance does not guarantee future results. For educational and informational purposes only. Not financial advice. Consult a licensed advisor.

What is the best stock screener?

For US equities, Finviz is the default for good reason: fast, dozens of filters, the clearest heat map anywhere, and a usable free tier. Koyfin is stronger if you want screening attached to real fundamentals depth. TradingView's screener is the natural choice if you already live in its charts. Zacks leans on its own ranking system, which is systematic but a composite you cannot open and inspect.

The choice matters far less than what you do next. Any of these will produce a competent shortlist, and none of them will tell you whether the reasoning that produced it has ever held up. Note too that screening logic does not transfer cleanly across asset classes: a crypto screen has no filings to filter on and has to run off on-chain data pulled straight from an indexed blockchain instead, which is a different discipline with a different set of traps.

Do screeners find undervalued stocks?

They find stocks that look statistically cheap on the metrics you chose, which is not the same thing. Genuine undervaluation means the market is wrong about future cash flows, and no filter can see that, because cheapness on a screen is a public fact rather than a private insight. What screens reliably surface is the pool where undervalued companies tend to live, mixed in with the value traps. Separating those two is the analysis, and it starts after the screen, not with it.

The short answer

Do stock screeners work? Yes, at narrowing. No, at deciding. Use one, spend the $40, and take the shortlist gratefully. Then take the rule behind that shortlist and put it on a bench: 20+ years of split- and dividend-adjusted daily data, realistic trading costs charged, plotted against buy-and-hold, with the drawdown you would actually have had to sit through drawn on the chart.

That is what Agenttrading does, in plain English rather than in code. Type the thesis the way you would say it, confirm the rule the bench restates back to you, and read the verdict: HELD UP, MIXED, or UNDERPERFORMED. The last one shows up often, and it stays as prominent as the other two, because a tool that cannot tell you your idea failed is not analysis.

The testing engine is described on backtesting software, whole-basket testing on portfolio backtesting, and the honest map of screeners, terminals, and assistants on stock analysis tools. If you are weighing a specific screener subscription, Finviz alternative compares the two approaches directly, and best AI trading software prices the entire category with July 2026 list prices.

Past performance does not guarantee future results. For educational and informational purposes only. Not financial advice. Consult a licensed advisor.